Menu
GWAS Study

Cross-ancestry GWAS defines the extended CYP2D6 locus as the principal genetic determinant of endoxifen plasma concentrations.

Khor CC, Winter S, Sutiman N et al.

36629403 PubMed ID
GWAS Study Type
497 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

KC
Khor CC
WS
Winter S
SN
Sutiman N
MT
Mürdter TE
CS
Chen S
LJ
Lim JSL
LZ
Li Z
LJ
Li J
SK
Sim KS
GB
Ganchev B
ED
Eccles D
EB
Eccles B
TW
Tapper W
ZN
Zgheib NK
TA
Tfayli A
NR
Ng RCH
YY
Yap YS
LE
Lim E
WM
Wong M
WN
Wong NS
AP
Ang PCS
DR
Dent R
TR
Tremmel R
KK
Klein K
SE
Schaeffeler E
ZY
Zhou Y
LV
Lauschke VM
EM
Eichelbaum M
SM
Schwab M
BH
Brauch HB
CB
Chowbay B
SW
Schroth W
Chapter II

Abstract

Summary of the research findings

The therapeutic efficacy of tamoxifen is predominantly mediated by its active metabolites 4-hydroxy-tamoxifen and endoxifen, whose formation is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6). Yet, known CYP2D6 polymorphisms only partially determine metabolite concentrations in vivo. We performed the first cross-ancestry genome-wide association study with well-characterized patients of European, Middle-Eastern, and Asian descent (n = 497) to identify genetic factors impacting active and parent metabolite formation. Genome-wide significant variants were functionally evaluated in an independent liver cohort (n = 149) and in silico. Metabolite prediction models were validated in two independent European breast cancer cohorts (n = 287, n = 189). Within a single 1-megabase (Mb) region of chromosome 22q13 encompassing the CYP2D6 gene, 589 variants were significantly associated with tamoxifen metabolite concentrations, particularly endoxifen and metabolic ratio (MR) endoxifen/N-desmethyltamoxifen (minimal P = 5.4E-35 and 2.5E-65, respectively). Previously suggested other loci were not confirmed. Functional analyses revealed 66% of associated, mostly intergenic variants to be significantly correlated with hepatic CYP2D6 activity or expression (ρ = 0.35 to -0.52), and six hotspot regions in the extended 22q13 locus impacting gene regulatory function. Machine learning models based on hotspot variants (n = 12) plus CYP2D6 activity score (AS) increased the explained variability (~ 9%) compared with AS alone, explaining up to 49% (median R2 ) and 72% of the variability in endoxifen and MR endoxifen/N-desmethyltamoxifen, respectively. Our findings suggest that the extended CYP2D6 locus at 22q13 is the principal genetic determinant of endoxifen plasma concentration. Long-distance haplotypes connecting CYP2D6 with adjacent regulatory sites and nongenetic factors may account for the unexplained portion of variability.

148 Singaporean Chinese ancestry individuals, 69 Lebanese ancestry individuals, 280 German ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

497
Total Participants
GWAS
Study Type
No
Replicated
East Asian, Greater Middle Eastern (Middle Eastern, North African or Persian), European
Ancestry
Singapore, Lebanon, Germany
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.